Milk Thistle

Clinical Summary

Milk thistle (Silybum marianum) produces silymarin, a mixture of flavonolignans dominated by silybin (50-70%). It has been used for liver conditions for over 2,000 years and is one of the most studied herbal supplements globally.

What the evidence actually shows: Silymarin is safe, well-tolerated, and has genuine antioxidant and anti-inflammatory activity. For NAFLD, it modestly improves liver enzymes (ALT ~8-15 U/L) but the 2025 Cochrane review rates the evidence as "low-certainty" and no study has shown fibrosis reversal or histological improvement. For type 2 diabetes, multiple meta-analyses confirm meaningful fasting glucose (-23 to -40 mg/dL) and HbA1c (-0.8 to -1.3%) reductions as adjunct therapy — though most data comes from Middle Eastern populations. IV silibinin remains the standard emergency treatment for Amanita mushroom poisoning.

What's new (2024-2026): Two human RCTs now show neuroprotective effects in Alzheimer's disease (PMIDs 39139290, 38353101) — the first human cognitive data ever. A new meta-analysis establishes nephroprotection as a clinical indication (PMID 40886393). JAMA Dermatology published a network meta-analysis identifying silymarin for chemotherapy hand-foot syndrome prevention (PMID 41779386). Novel formulations (micellar, krill oil-based) show improved human bioavailability. Korean real-world data (PMID 40708304) adds large-scale evidence for hepatoprotection.

Who benefits most: People with NAFLD + T2DM (dual indication), patients on hepatotoxic medications (chemotherapy, anti-TB drugs, methotrexate), and anyone with confirmed elevated liver enzymes seeking adjunct support. For healthy people without liver disease, the evidence for "liver support" is thin.

The bioavailability paradox: Standard silymarin has poor systemic bioavailability (23-47%), but high hepatic first-pass extraction. This may actually be a feature, not a bug — the compound concentrates in the liver (its target organ) during first-pass metabolism. Phytosome formulations bypass this, which may be counterproductive for liver indications specifically.

Indications & Evidence

Reading this table: Stars = evidence volume/quality. Type = causal relationship (see legend). BH = Bradford Hill criteria met (/9). Safety = FAERS/trial signals for THIS indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., SE (surrogate endpoint) caps at 3/5; AHE (animal→human) caps at 2/5.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

5/5 Multiple large RCTs + meta-analyses | 4/5 Several human RCTs | 3/5 Some human pilot/small RCT data | 2/5 Animal or very limited human | 1/5 None/debunked

Key rating changes from prior version: NAFLD downgraded 4/5→3/5 (Cochrane: "low-certainty"; surrogate endpoint trap — enzyme improvement ≠ histology benefit). Metabolic syndrome downgraded 4/5→3/5 (fewer dedicated MetS trials; most data extrapolated from T2DM). Chemoprotection upgraded 3/5→4/5 (new RCTs: PMID 39110237, 39232773, 41779386). Neuroprotection upgraded 2/5→3/5 (first human RCTs: PMID 39139290, 38353101). Nephroprotection upgraded animal-only→3/5 (meta-analysis + RCTs).

Prescribing

Dosing Table

Formulation Table

Condition-Specific Protocols

NAFLD/MASLD Protocol

Evidence: 3/5 | Key PMIDs: 40552569, 38579127, 31536511, 39097726

Phase 1: Initiation (Weeks 1-4)

• Dose: 140 mg silymarin TID with meals (420 mg/day)
• Baseline labs: CMP, LFTs (ALT, AST, GGT, ALP, bilirubin), FibroScan if available
• Goal: Establish tolerability; GI side effects usually appear in first 2 weeks

Phase 2: Therapeutic (Weeks 5-12)

• Maintain 420 mg/day; increase to 600 mg/day if well-tolerated and enzymes unchanged at 6 weeks
• Labs: LFTs at week 6 and week 12
• Expected: ALT reduction 8-15 U/L (modest); improved stiffness on elastography

Phase 3: Maintenance (Week 12+)

• Continue 420 mg/day if enzymes improved
• Labs: LFTs q3-6 months
• Reassess: If no enzyme improvement after 12 weeks on 600 mg/day, consider phytosome formulation before discontinuing

Stop/Reassess: If ALT/AST >3× baseline, reassess underlying condition. Silymarin does NOT reverse fibrosis — lifestyle modification (weight loss, exercise, diet) remains primary therapy.

T2DM Glycemic Control Protocol

Evidence: 4/5 | Key PMIDs: 33019400, 39855603, 40439602, 38396727

Phase 1: Initiation (Weeks 1-2)

• Dose: 200 mg/day silymarin with largest meal
• Baseline: FBG, HbA1c, fasting insulin, lipid panel
• Monitor glucose daily for 2 weeks (additive hypoglycemia risk with metformin/sulfonylureas)

Phase 2: Therapeutic (Weeks 3-24)

• Increase to 400-600 mg/day divided BID-TID
• Labs: FBG weekly × 4 weeks, then monthly; HbA1c at 12 and 24 weeks
• Expected: FBG -23-40 mg/dL; HbA1c -0.8-1.3% (effects most pronounced in Middle Eastern studies)

Phase 3: Maintenance (Week 24+)

• Continue effective dose; HbA1c q3 months
• If HbA1c drops >0.5%, discuss diabetes medication dose reduction with physician

Drug Interaction Timing: Take silymarin with meals; no specific spacing needed with metformin. If on sulfonylureas/insulin, glucose monitoring is critical due to additive effect.

Chemoprotection Protocol

Evidence: 4/5 | Key PMIDs: 39110237, 39232773, 40066113, 41779386

Pre-treatment: Start silymarin 420-600 mg/day at least 1 week before chemotherapy initiation During treatment: Continue throughout chemotherapy course; 140-200 mg TID with meals Post-treatment: Continue 4 weeks after last chemotherapy cycle Monitoring: LFTs and renal function per oncology protocol; compare to pre-silymarin baseline Critical: Discuss with oncologist before starting — theoretical CYP3A4/P-gp interactions could affect some chemotherapy drug levels. The JAMA Dermatology NMA (PMID 41779386) supports nano-silymarin specifically for hand-foot syndrome prevention.

Amanita Poisoning Protocol

Evidence: 5/5 | Emergency use

Immediate: Call poison control. Oral silymarin is INEFFECTIVE — IV silibinin (Legalon SIL) required.

• Dose: 20-50 mg/kg/day IV continuous infusion or divided q6h
• Duration: 48-96 hours; extend if enzymes remain elevated
• Timing: Administer ASAP after suspected ingestion (ideally <48h)
• Adjuncts: Activated charcoal (if <1-2h), penicillin G, supportive care
• Availability: EU specialized centers; US via emergency IND/compassionate use
• New data (PMID 41378447): Poison center analysis suggests oral silymarin may have some effect in acute hepatotoxic mushroom poisoning — but IV remains standard of care.

Safety

Interactions Table

CYP450 profile: Moderate CYP2C9 inhibition (most clinically significant for warfarin), weak-moderate CYP3A4 inhibition, weak CYP2C19 and CYP1A2 inhibition. Some evidence of mild CYP3A4 induction with chronic use (conflicting data). P-glycoprotein inhibition increases absorption of P-gp substrates.

Contraindications

• Absolute: Known Asteraceae/Compositae allergy (ragweed, chrysanthemums, marigolds, daisies — cross-reactivity risk); active biliary obstruction (stimulates bile flow)
• Relative: Decompensated cirrhosis (Child-Pugh C) — unpredictable drug metabolism; hormone-sensitive cancers (ER+ breast, endometrial) — weak estrogenic activity in vitro, clinical significance unclear; pregnancy/lactation (insufficient safety data); severe renal failure GFR <15 (theoretical accumulation)

Adverse Effects

Common (1-10%): GI disturbances — diarrhea (5-10%), bloating/gas (3-5%), nausea (2-4%), dyspepsia (2-3%), abdominal fullness (2-3%). Dose-dependent; take with food or switch to phytosome. Laxative effect from bile stimulation (5-8%).

Uncommon (0.1-1%): Headache (1%), pruritus (0.5-1%, possibly from increased bile flow), arthralgia (rare), weakness/fatigue (rare).

Rare (<0.1%): Allergic reactions (rash, urticaria, anaphylaxis — higher risk with Asteraceae allergy), menstrual irregularities (anecdotal), severe allergic dermatitis (occupational exposure case reports).

Hepatotoxicity paradox: Rare case reports of suspected DILI exist but causality is difficult to establish — confounded by underlying liver disease in virtually all cases. Very rare if product is authentic and unadulterated.

Safety profile: Very wide therapeutic index. No severe toxicity at doses up to 2,100 mg/day. No dependence, withdrawal, or cumulative toxicity. Up to 41 months studied in clinical trials. No carcinogenic potential; anticancer properties in preclinical models.

FAERS Signal Table

FAERS interpretation: Total silymarin reports: ~2,349; milk thistle reports: ~6,584. In the vast majority, silymarin/milk thistle is listed as concomitant (not suspect). Reports co-list chemotherapy agents, immunosuppressants, and antivirals as primary suspects. Reaction profiles mirror the primary drugs. Silybin-specific reports (N=51) are almost entirely concomitant with cancer drugs. Assessment: No unexpected safety signals. This is textbook FAERS supplement noise — the supplement is taken alongside drugs that cause the reported reactions.

Monitoring Table

Warning thresholds: ALT/AST >3× baseline → reassess (silymarin may be ineffective, condition worsening). INR >4.0 → reduce warfarin, consider discontinuing silymarin. FBG <70 → reduce diabetes medications.

Special Populations

Renal Impairment

Hepatic Impairment

Pregnancy & Lactation

• No controlled studies in pregnant women. Animal data: no teratogenicity up to 2,500 mg/kg.
• Weak estrogenic activity in vitro — clinical significance unclear.
• Traditional use as galactagogue (the name "milk thistle" derives from white leaf veins); no RCTs confirm efficacy for lactation (PMID 41350450).
• Recommendation: Avoid during pregnancy and lactation unless prescribed by physician. Obtain antioxidants from food sources.

Pediatric

• No safety or efficacy data in children <18 years. Not recommended.

Synergies & Stacking

No known antagonistic nutrient interactions.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No dedicated pharmacogenomic studies of silymarin response exist. This is a major research gap. The above inferences are from known metabolic pathways, not compound-specific studies.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mildly positive / "can't hurt" baseline across ~hundreds of reports. ~55-60% report some perceived benefit, ~25-30% take it as "insurance" without noticing effects, ~10-15% report side effects or skepticism.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: None. Milk thistle is a commodity ingredient, not associated with MLM companies.
• Influencer concentration: No single influencer drives sales. "Old guard" supplement with decades-long steady demand.
• Astroturfing signals: None detected. Forum discussions appear organic with genuine disagreement.
• Commercial bias: ConsumerLab testing shows some products don't contain claimed silymarin amounts — label accuracy is a legitimate concern.
• PropeciaHelp warning: Isolated forum post about "persistent side effects" — unique hormonal sensitivity context (post-finasteride syndrome), not generalizable.

Folk vs Clinical Reality Check

Community experience broadly aligns with clinical data for liver enzyme support and GI effects. The biggest divergence is hangover prevention — the #1 folk use (especially in Japan) has essentially zero clinical backing. Bodybuilders overestimate silymarin's capacity for steroid-induced hepatotoxicity (TUDCA is superior). The community's growing preference for phytosome formulations is supported by PK data but may be counterproductive for liver-specific indications (phytosome bypasses hepatic first-pass, which is where silymarin concentrates). Acne reports are polarized — some users see clearing while others report flares, consistent with the limited and mixed clinical data.

Deep Dive: Mechanisms & Research

Hepatocellular protection: Silymarin integrates into hepatocyte membranes, increasing structural integrity and preventing toxin entry. It scavenges ROS/RNS, increases intracellular glutathione by up to 35%, and inhibits lipid peroxidation. RNA polymerase I stimulation promotes hepatocyte regeneration.

Anti-inflammatory: NF-κB inhibition suppresses TNF-α, IL-2, IL-4, IL-6, IFN-γ. COX-2 inhibition reduces prostaglandin synthesis. iNOS suppression reduces inflammatory NO.

Metabolic regulation: Enhances insulin receptor signaling, improves GLUT4 translocation, reduces hepatic glucose production, activates AMPK pathway. Anti-inflammatory effects on pancreatic beta cells.

Novel mechanisms (2024-2026):

• Ferroptosis inhibition — silymarin targets xCT-mediated amino acid metabolism in MAFLD (PMID 41654271) and FTH1 modulation in renal fibrosis (PMID 40541121). Ferroptosis is emerging as a key mechanism across liver and kidney pathology.
• STING pathway inhibition — silybin attenuated neuroinflammation via STING inhibition in subarachnoid hemorrhage (PMID 39986195).
• Gut microbiota metabolites — silibinin-derived metabolites enriched (R)-2,3-dihydroxy-isovalerate, ameliorating colitis via GAT-3/RARβ/RORγt axis (PMID 40801260, ISME Journal).
• Cardiac troponin binding — silybin B binds cardiac muscle troponin and restores lusitropy in cardiomyopathy mutations (PMID 39735723).
• Caspase-11 inflammasome — silymarin targets noncanonical inflammasome in sepsis (PMID 41101553, Korean research).

Bioavailability challenge: Poor aqueous solubility, extensive first-pass metabolism (60-80%), active P-gp efflux, rapid conjugation. Enterohepatic recirculation extends hepatic exposure. New formulations show promise: micellar (PMID 40733088) and krill oil-based (PMID 41583423) demonstrate enhanced human PK.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Total registered trials: ~95 unique across all search terms. ~45 completed, ~12 recruiting/active, ~10 terminated/withdrawn.

Regulatory Status

• FDA: Not approved as a drug. Marketed as dietary supplement under DSHEA. Legalon SIL available via emergency IND for Amanita poisoning.
• EMA: No centralized authorization. German Commission E monograph (1986) approves for toxic liver damage and adjunctive chronic liver disease. EMA HMPC community herbal monograph recognizes traditional use.
• Germany: Legalon (Rottapharm/Madaus) approved OTC hepatoprotective drug.
• China: Silibinin capsules approved in Chinese Pharmacopoeia for liver protection.
• South Korea: Marketed by Bukwang Pharmaceutical as hepatoprotective drug.
• Taiwan: Silymarin listed as prescription hepatoprotective.
• EASL 2024 MASLD guidelines: Nutraceuticals (including silymarin) "cannot be recommended" due to insufficient evidence of histological improvement.
• Chinese TB guidelines 2024 (PMID 39497389): Silymarin mentioned as hepatoprotective option for anti-TB DILI.

Regulatory context: Silymarin has never been through the NDA process because it is a non-patentable botanical extract — the economics of drug development don't support it. This is a commercial decision, not a safety failure. Several countries (Germany, China, Korea) have national-level approval based on decades of clinical use.

Ataraxia Verdict (as of 2026-04-16)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

Appeal to Mechanism (HIGH confidence): The file's extensive mechanistic descriptions (NF-κB, AMPK, glutathione, RNA polymerase I) create an impression of proven efficacy, but clinical translation is incomplete for most pathways. Mechanism ≠ clinical benefit.

Hasty Generalization (MEDIUM): T2DM meta-analysis results (HbA1c -1.07%) are heavily weighted by Iranian/Iraqi studies. The file previously rated this as 4/5 without adequately flagging generalizability concerns.

Surrogate Endpoint Trap (HIGH): NAFLD was rated 4/5 based on ALT/AST reduction — but Navarro 2019 showed high-dose silymarin did NOT improve NASH histology. Enzyme improvement is a surrogate marker, not a clinical endpoint. The Cochrane review (Wang 2025) correctly identifies this as "low-certainty evidence."

Appeal to Tradition (LOW): "2,000 years of use" is cited frequently but traditional preparations (teas, seeds) bear little resemblance to modern standardized extracts.

Evidence Gaps

• No dose-response studies — minimum effective dose unknown
• No pharmacogenomic studies — who responds vs. doesn't is completely unstudied
• No Western population diabetes RCTs — all major glycemic data from Middle East
• No long-term outcomes data beyond 41 months
• No head-to-head formulation comparisons in clinical outcomes (standard vs phytosome vs micronized)
• Neuroprotection needs replication — 2 small Iranian RCTs are promising but not enough
• Pediatric data completely absent
• Pregnancy safety data completely absent
• Microbiome modulation just beginning (1 human RCT)

Bias Flags (Mode 4: First Principles)

The bioavailability assumption is backwards: The supplement industry frames low systemic bioavailability as a problem requiring expensive phytosome solutions. But silymarin's target is the liver, and high hepatic first-pass extraction means the compound concentrates in its target organ. Phytosome formulations that bypass first-pass may actually reduce hepatic exposure — the opposite of what's desired for liver indications. This reframes the $45/month phytosome premium as potentially counterproductive for the primary use case.

"Liver support" for healthy people is a solution in search of a problem. The liver has enormous regenerative capacity. Unless there is actual injury (elevated enzymes, fatty liver, drug exposure), supplemental hepatoprotection in a healthy person is addressing a non-existent problem.

Evidence base is regionally concentrated: The strongest clinical data for glycemic control comes from Iran and Iraq. Dietary patterns, genetic background, and baseline metabolic status differ substantially from Western populations. Effect sizes may not replicate.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: "Liver support" and "detox" framing is ubiquitous in supplement marketing. The liver doesn't need "detoxing" in healthy people. Proprietary blends and "clinical strength" claims are common. The standardization norm of "80% silymarin" creates false precision — silymarin itself varies in composition.
• Influencer economics: No significant influencer ecosystem. Milk thistle is a commodity supplement — no viral hype cycles, no MLM involvement, no concentrated promotion.
• Counter-narrative manipulation: No active pharma fearmongering against milk thistle (unlike some other supplements). The compound is too cheap and widespread to be a competitive threat to any pharmaceutical.
• Cui bono summary: Supplement manufacturers benefit from the "liver support" narrative (milk thistle is a top-20 global supplement). Phytosome patent holders (Indena SpA) benefit from the bioavailability narrative. No one profits significantly from discouraging milk thistle use.
• Red team highlight: The most concerning angle is surrogate endpoint inflation — the supplement industry and many studies present ALT/AST reduction as equivalent to "liver improvement," when the Cochrane review and Navarro 2019 show this doesn't translate to histological or clinical benefit. This is the same pattern that plagued vitamin E (raised antioxidant markers, didn't prevent disease) and beta-carotene (raised levels, increased cancer).

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 5/10 — moderate evidence clustered on hepatoprotection in pathological liver states (elevated enzymes, drug-induced hepatotoxicity, NAFLD adjunct) and T2DM adjunctive use; no convincing evidence for healthy-liver "support," so general-population utility is narrow.
• Opportunity cost: $15/month (standard extract), 3× daily dosing complexity, 5-10% chance of GI side effects
• Verdict: CONDITIONAL
• Conditions: (1) Confirmed elevated liver enzymes (ALT/AST) from any cause → yes; (2) T2DM as adjunct to standard therapy → yes; (3) On hepatotoxic medications (chemo, anti-TB, methotrexate) → yes; (4) NAFLD as adjunct to lifestyle modification → reasonable; (5) Healthy person wanting "liver support" → skip (no evidence of benefit)

Bottom Line

Milk thistle is safe, cheap, and genuinely useful for specific clinical situations — T2DM adjunct therapy, chemoprotection, and drug-induced hepatotoxicity prevention all have solid evidence. For NAFLD, it helps enzyme numbers but doesn't fix the underlying disease (only lifestyle modification does that). The Alzheimer's data is the most exciting new development but needs replication. For healthy people without liver disease, diabetes, or hepatotoxic drug exposure, the evidence for routine supplementation is thin. The compound's greatest strength — an excellent safety profile over decades of use — is also what makes it easy to recommend when there IS an indication. Don't take it for vague "liver support." Take it when you actually need hepatoprotection.

Practical Notes

Brands & Product Selection

Quality markers: Look for USP Verified, NSF Certified for Sport (athletes), or ConsumerLab Approved. Standardization should be 70-80% silymarin with silybin content ≥30% of silymarin fraction. Heavy metal limits: Pb <0.5 ppm, As <0.5 ppm, Hg <0.1 ppm, Cd <0.5 ppm.

Reputable options (not endorsements — verified third-party testing):

• Thorne Research — Siliphos (phytosome) and standard extract
• Jarrow Formulas — Milk Thistle 150mg (standard); affordable
• NOW Foods — Silymarin (various strengths; some USP verified)
• Pure Encapsulations — Standardized extract
• Life Extension — European Milk Thistle

Red flags: Proprietary blends, "liver detox" multi-herb blends, no third-party testing, no silymarin standardization claimed, MLM/pyramid scheme products, suspiciously low prices.

Storage & Handling

• Room temperature (15-25°C). Protect from direct sunlight (UV degrades flavonolignans). Keep dry; avoid bathroom storage. Shelf life: 2-3 years unopened, 18-24 months after opening. Degradation signs: browning, unusual odor, clumping.

Palatability & Compliance

• Capsule/tablet preferred (convenient, no taste issues). Powder taste: mildly bitter, slightly astringent — mask with chocolate protein shakes or berry smoothies. Liquid tinctures: strong bitter taste (glycerin-based slightly sweeter). Link dosing to meals for compliance and absorption.

Exercise & Circadian Timing

No specific exercise or circadian interactions. No performance-enhancing effects. No sedative or stimulant properties. Take at any time with meals. Consistency matters more than specific timing.

Reference Ranges (Expected Biomarker Changes)

Cost

• Standard extract 420 mg/day: ~$0.50/day, ~$15/month
• Phytosome 240 mg/day: ~$1.50/day, ~$45/month
• Micronized 420 mg/day: ~$0.80/day, ~$24/month
• Best value: Standard extract (proven efficacy, lowest cost). Phytosome premium justified only for malabsorption or documented non-response to standard.

What We Don't Know

• Minimum effective dose — no dose-response studies exist
• Who responds and who doesn't — zero pharmacogenomic data; no biomarkers predict response
• Whether T2DM results replicate in Western populations — nearly all data from Middle East
• Whether enzyme improvement translates to long-term outcomes — no study >41 months; no mortality data
• Whether phytosome actually produces better clinical outcomes — better PK proven, clinical superiority not
• Whether the neuroprotection signal is real — 2 small Iranian RCTs need independent replication
• Exact mechanism of insulin sensitization — AMPK activation is proposed but not confirmed in humans
• Why individual variation is so large — microbiome? genetics? diet? formulation quality?
• Pediatric safety and dosing — completely unstudied
• Pregnancy safety — completely unstudied; animal data reassuring but insufficient
• Long-term effects of new formulations (micellar, krill oil, nano) — PK data only; no outcome trials
• Whether gut microbiome modulation (Jin 2024) is a real therapeutic mechanism or artifact
• Whether silymarin actually reaches the brain at therapeutic concentrations — the AD RCTs are promising but mechanism of CNS access is unclear

References

Systematic Reviews & Meta-Analyses

1. Wang Z et al. (2025). Silymarin for NAFLD. Cochrane Database Syst Rev 1(1):CD012790. PMID: 40552569 — Low-certainty evidence for enzyme improvement; no mortality benefit
2. Li W et al. (2024). Silymarin for NAFLD: systematic review and meta-analysis. Medicine 103(14):e37752. PMID: 38579127 — ALT -8.84 U/L (p<0.001)
3. Xiao X et al. (2020). Silymarin on metabolic syndrome: meta-analysis of RCTs. Complement Ther Med 50:102366. PMID: 33019400 — FBG -26.86 mg/dL; HbA1c -1.07%
4. Yin S et al. (2025). Silymarin on insulin resistance/sensitivity: meta-analysis. Diabetes Res Clin Pract. PMID: 39855603 — Confirms insulin-sensitizing effect
5. Miao R et al. (2025). Bayesian NMA: curcumin, resveratrol, silymarin, berberine for T2DM. Phytother Res. PMID: 40439602 — Ranks silymarin among effective botanicals
6. Frounchi N et al. (2025). Nephroprotective effects of silymarin: first meta-analysis. Biochemistry (Mosc). PMID: 40886393 — Confirms renal protection
7. Baskarane H et al. (2026). Preventing chemo hand-foot syndrome: NMA. JAMA Dermatol. PMID: 41779386 — Silymarin identified as effective intervention
8. Shahsavari K et al. (2025). Silymarin for liver injury: meta-analysis. BMC Complement Med Ther. PMID: 40221681 — Dosing/timing optimization
9. Zhang Z et al. (2025). Silymarin vs lifestyle/medications for NAFLD. Asia Pac J Clin Nutr. PMID: 40738719 — Comparative efficacy
10. Cragg A et al. (2026). Herbal galactagogues for preterm mothers: review. Eur J Clin Nutr. PMID: 41350450 — Insufficient evidence for lactation

Landmark RCTs

11. Navarro VJ et al. (2019). Silymarin in NASH: RCT. PLoS One 14(9):e0221683. PMID: 31536511 — High-dose did NOT improve histology (important negative)
12. Fried MW et al. (2012). Silymarin for HCV: RCT (NCCIH-funded). JAMA 308(3):274-282. PMID: 22797645 — No benefit in HCV (important negative)
13. Jin H et al. (2024). Silymarin modulating gut microbiota in MASLD: RCT. Eur J Pharmacol 977:176690. PMID: 39097726 — Reduced stiffness + microbiota modulation
14. MacDonald-Ramos K et al. (2024). Silymarin in obese women: RCT. Biomed Pharmacother 173:116338. PMID: 38396727 — Reduced HOMA-IR
15. Rustamzadeh A et al. (2024). Silymarin + rosuvastatin in Alzheimer's: RCT. IBRO Neurosci Rep. PMID: 39139290 — Improved amyloid carriers (first AD RCT)
16. Navabi SM et al. (2024). Adjunctive silymarin in Alzheimer's: RCT. Nutr Neurosci. PMID: 38353101 — Reduced disease severity and inflammation
17. Fatemi Shandiz A et al. (2025). Silymarin preventing doxorubicin hepatotoxicity: RCT. J Oncol Pharm Pract. PMID: 39110237 — Positive hepatoprotection
18. Erfanian SS et al. (2024). Silymarin hepatorenal protection during chemo: RCT. BMC Complement Med Ther. PMID: 39232773 — Positive protection
19. Karbasforooshan H et al. (2024). Nano-silymarin preventing HFS/neuropathy: RCT. Iran J Pharm Res. PMID: 40066113 — Positive (nano formulation)
20. Soleimani V et al. (2026). Nano-silymarin preventing vancomycin nephrotoxicity: RCT. Naunyn Schmiedebergs Arch Pharmacol. PMID: 40762702 — Positive nephroprotection
21. Karimian A et al. (2025). Silymarin for vancomycin nephrotoxicity: pilot RCT. Naunyn Schmiedebergs Arch Pharmacol. PMID: 39311921 — Positive
22. Valipour R et al. (2024). Vitamin D + silymarin for BPH: RCT. Urologia. PMID: 39221555 — Improved LUTS
23. Grant JE et al. (2024). Silymarin for gambling disorder: RCT. Clin Neuropharmacol. PMID: 38478366 — Novel psychiatric application
24. Feily A et al. (2024). Silymarin + hair follicle transplant for vitiligo: RCT. J Cosmet Dermatol. PMID: 39161267 — Positive repigmentation
25. Ponce Martinez C et al. (2024). Silibinin lipase inhibition + microbiota: RCT. Int J Mol Sci. PMID: 39684564 — Microbiome modulation in healthy volunteers

Clinical Studies & Combination Trials

26. Gheonea DI et al. (2025). Silymarin + VitE + phospholipid in MASLD. Int J Mol Sci. PMID: 40564891 — Combination improved steatosis/fibrosis
27. Elgendy EM et al. (2025). Curcuminoids + silymarin for hepatic impairment. Chem Biodivers. PMID: 40513108 — Additive hepatoprotection
28. Shaker MK et al. (2025). Phyllanthus + Silybum in NASH: Phase II. BMC Complement Med Ther. PMID: 39789561 — Combination therapy
29. Li BY et al. (2024). TCM combo (Silybum + Pueraria + Salvia) for NAFLD: RCT. Clin Nutr ESPEN. PMID: 38879879 — Positive
30. Zugravu GS et al. (2024). Silymarin in active RA: pilot. Medicina. PMID: 38929616 — Novel autoimmune application
31. Draelos ZD et al. (2024). Silymarin serum for facial acne. J Drugs Dermatol. PMID: 38564394 — Clinical improvement
32. Santamarina AB et al. (2024). Nutraceutical with silymarin for mood/sleep. Nutrients. PMID: 39339649 — Pilot: improved perception
33. Jang BK et al. (2025). Korean real-world cohort: silymarin (Legalon). Gut Liver. PMID: 40708304 — Large-scale real-world evidence
34. Chang C et al. (2025). Micellar silymarin: human PK crossover. Pharmaceutics. PMID: 40733088 — Enhanced bioavailability
35. Engelhart-Jentzsch K et al. (2026). Krill oil milk thistle: human PK. Food Nutr Res. PMID: 41583423 — Enhanced bioavailability
36. Tangsuwanaruk T et al. (2026). Oral silymarin in mushroom poisoning. Clin Toxicol. PMID: 41378447 — Poison center data
37. Bosch-Barrera J et al. (2025). Silibinin overcoming immunoresistance: case. Front Med. PMID: 40703266 — Brain mets case report

Reviews & Mechanism Studies

38. MacDonald-Ramos K et al. (2020). Silymarin insulin-sensitizing review. Phytomedicine 77:153268. PMID: 32950646
39. Vahabzadeh M et al. (2018). Silymarin and metabolic syndrome. J Sci Food Agric 98(13):4816-4823. PMID: 29736939
40. Bellavite P et al. (2023). Berberine, quercetin, silymarin: insulin/CV review. Molecules 28(11):4491. PMID: 37298967
41. Abenavoli L et al. (2018). Milk thistle overview. Phytother Res 32(11):2202-2213. PMID: 30080294
42. Flora K et al. (1998). Milk thistle for liver disease. Am J Gastroenterol 93(2):139-143. PMID: 9468229
43. Polyak SJ et al. (2013). Silymarin in HCV: mechanism. Hepatology 57(3):1262-1271. PMID: 23213025
44. Vargas-Mendoza N et al. (2014). Hepatoprotective effect of silymarin. World J Hepatol 6(3):144-149. PMID: 24672644
45. Flaig TW et al. (2007). High-dose silybin-phytosome in prostate cancer. Prostate 67(6):643-651. PMID: 17077998
46. Soto C et al. (2010). Silymarin: pancreatic recovery in rats. Life Sci 86(5-6):167-173. PMID: 20006626
47. Eminzade S et al. (2008). Silymarin hepatoprotection from TB drugs. Nutr Metab 5:18. PMID: 18554392